Improved downstream operation through formulation innovation

Lead Participant: Arecor Limited


The aim of this project is to provide new formulations that bring about a step change in biopharmaceutical yield and quality by improving product stability through the most protein degradation sensitive/impactful areas of downstream processing (DSP). This is a novel approach to improving process efficiency as currently protein products have comparatively limited stability in the existing default DSP buffers. To develop a new platform of formulations and formulation strategies this collaborative project will bring together the formulation expertise of Arecor with the DSP expertise at Fujifilm Diosynth Biotechnologies (FDB) and The Centre for Process Innovation (CPI). The platform of formulations and the formulations strategies developed can then be applied to reduce production cost of all biologics to pharma and ultimately cost to healthcare providers. These new formulations may also enable the production of biotherapeutics that are currently very difficult/impossible to manufacture.

Lead Participant

Project Cost

Grant Offer

Arecor Limited, Cambridge, United Kingdom £895,705 £ 537,423


Centre for Process Innovation Limited, REDCAR £947,412 £ 947,412
Fujifilm Diosynth Biotechnologies UK Limited, BILLINGHAM £147,476 £ 73,738


10 25 50